Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
American Society of Hematology (ASH)
The
American Society of Hematology
(
ASH
) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal
Blood
, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal,
Blood Advances
.
Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Phase 2 Study
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Ibrutinib versus Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle-Cell Lymphoma (MCL)
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Syk Inhibitor Entospletinib Monotherapy in CLL/SLL: Phase 2 Trial Results
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Idelalisib plus Bendamustine/Rituximab versus Bendamustine/Rituximab in Relapsed/Refractory CLL: Results of a Phase 3 Study
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study
ASH 2015 – Castleman's Disease, Lymphoma & CLL
Read More ›
Adding Rituximab to CHOP Improves Clinical Outcomes in Mantle-Cell Lymphoma
ASH 2014 – Castleman's Disease
Read More ›
Ibrutinib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
ASH 2014 – Castleman's Disease
Read More ›
Safety and Efficacy of Ibrutinib plus Rituximab in Relapsed Mantle-Cell Lymphoma
ASH 2014 – Castleman's Disease
Read More ›
Page 40 of 44
37
38
39
40
41
42
43
Conference Coverage Proudly Presented by
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us